Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: stockdoc77 who wrote (38480)	1/6/2017 7:01:02 PM
From: drtom1234	Read Replies (1) \| Respond to of 63292

You're assuming venbio won't sell off 130, vmab, emab, or international rights to 132 as a way to raise capital.

To: stockdoc77 who wrote (38480)	1/6/2017 7:41:59 PM
From: idahoranch1	4 Recommendations Recommended By corndog EMU2 ladyPI plhky3465 Read Replies (1) \| Respond to of 63292

In the CC with venBio, Behzad was asked a couple of times about capital. He said that if the slate of candidates they proposed were voted in, the board would need to look at all options and that until they knew what was "under the hood" it wasn't possible to know the best way to go. He said that if 132 data continued to impress, that the science behind it was sound, and if it was sound there, then there was likely other good things in the pipeline. He mentioned licensing 132, and then brought up licensing it for all but the US market. I didn't get the sense at all that they wanted to keep it all in house if that became risky or too expensive (excess dilution, he stressed that he did not like dilution and especially bad dilution). For anyone that knows how to run a business and watches people who know how, watching this company and looking at the history of the lack of deals while touting a "robust and diversified pipeline" and doing horrible financings over the last 9 years, it's a slam dunk to see that the markets valuation is heavily discounted for that reason alone. I do think 132 has tremendous potential, and will eventually be seen in a better stock price. But it will never get to where it should with the business approach that has been in place for many years. To get anywhere near the PPS that should be warranted, there needs to be a shareholder considerate BOD in place, not a management considerate BOD. I believe that venBio saw the chance to change how business is being done at headquarters and be rewarded by the street when those changes start to show up in the boards and managements decisions. Again, I hope for a change in the BOD, not handpicked by Dr. Goldenberg, we've always had that. Then I hope Dr. Goldenberg and the new board find common ground and work together to make this company what it always seemed to have the potential to be. If that doesn't happen, then I'll accept whatever delay might happen because Doc picks up his toys and goes home. I happen to think there are a lot of employees that want to ride a successful 132 and will help keep things moving no matter which way it goes.